CN117599068A - 12-酮基石胆酸在制备抗咽峡炎链球菌产品中的应用 - Google Patents
12-酮基石胆酸在制备抗咽峡炎链球菌产品中的应用 Download PDFInfo
- Publication number
- CN117599068A CN117599068A CN202311376447.4A CN202311376447A CN117599068A CN 117599068 A CN117599068 A CN 117599068A CN 202311376447 A CN202311376447 A CN 202311376447A CN 117599068 A CN117599068 A CN 117599068A
- Authority
- CN
- China
- Prior art keywords
- streptococcus
- product
- angina
- ketolithocholic acid
- growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000194017 Streptococcus Species 0.000 title claims abstract description 45
- CVNYHSDFZXHMMJ-UHFFFAOYSA-N 12-keto-lithocholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(=O)C2 CVNYHSDFZXHMMJ-UHFFFAOYSA-N 0.000 title claims abstract description 36
- CVNYHSDFZXHMMJ-VPUMZWJWSA-N 12-ketolithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)C(=O)C1 CVNYHSDFZXHMMJ-VPUMZWJWSA-N 0.000 title claims abstract description 36
- 206010002383 Angina Pectoris Diseases 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title claims description 8
- 208000015181 infectious disease Diseases 0.000 claims abstract description 13
- 201000010099 disease Diseases 0.000 claims abstract description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 12
- 230000002401 inhibitory effect Effects 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 12
- 239000000654 additive Substances 0.000 claims description 10
- 230000000996 additive effect Effects 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- 239000003674 animal food additive Substances 0.000 claims description 3
- 239000000022 bacteriostatic agent Substances 0.000 claims description 3
- 239000002778 food additive Substances 0.000 claims description 3
- 235000013373 food additive Nutrition 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 8
- 229960005091 chloramphenicol Drugs 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 241001134658 Streptococcus mitis Species 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 206010000269 abscess Diseases 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 238000011481 absorbance measurement Methods 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000194008 Streptococcus anginosus Species 0.000 description 1
- 241000194026 Streptococcus gordonii Species 0.000 description 1
- 206010044016 Tooth abscess Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000006781 columbia blood agar Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 201000003515 dental abscess Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 238000005142 microbroth dilution method Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000004563 wettable powder Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N45/00—Biocides, pest repellants or attractants, or plant growth regulators, containing compounds having three or more carbocyclic rings condensed among themselves, at least one ring not being a six-membered ring
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
- A01P3/00—Fungicides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/184—Hormones
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Polymers & Plastics (AREA)
- Plant Pathology (AREA)
- Food Science & Technology (AREA)
- Wood Science & Technology (AREA)
- Environmental Sciences (AREA)
- Pulmonology (AREA)
- Pest Control & Pesticides (AREA)
- Mycology (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Animal Husbandry (AREA)
- Neurology (AREA)
- Agronomy & Crop Science (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Dentistry (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明公开了12‑酮基石胆酸在制备抗咽峡炎链球菌产品中的应用；本发明首次发现了12‑酮基石胆酸对咽峡炎链球菌能够抑制咽峡炎链球菌的生长，且IC50为3.805μg/mL；因此12‑酮基石胆酸可以用于制备抗咽峡炎链球菌的产品，从而有效治疗咽峡炎链球菌感染或由咽峡炎链球菌感染导致的疾病；具有很好的应用前景。
Description
技术领域
本发明属于生物制药技术领域，具体涉及12-酮基石胆酸在制备抗咽峡炎链球菌产品中的应用。
背景技术
咽峡炎链球菌(Streptococcus anginosus,S.anginosus)作为条件致病菌，是引起感染的常见菌之一，临床变现不一，治疗方式及疾病预后存在显著差异，常引起各器官、组织的脓肿及其他部位的化脓性感染。既往研究证实，咽峡炎链球菌可产生多种体外毒素引起侵袭性化脓性感染，一旦入侵血液后可随血液循环遍及全身，引起全身感染、中毒和全身炎症反应的严重感染性疾病，病情常较为凶险，若不能及时进行抗感染治疗，预后较差。细菌耐药是全球问题，为了减少抗菌药物使用，预防耐药菌的产生，新药的开发具有重要的参考价值。
胆汁酸是胆汁里的一个有效成分，是参与胆汁消化功能的重要成分之一。其含量变化在肝脏病诊断中具有重要的参考价值，此外还具有抑制肿瘤的效果。12-酮基石胆酸是肠道中最重要的次级胆汁酸之一，但是目前未见12-酮基石胆酸在制备抗咽峡炎链球菌产品中应用的报道。
发明内容
本发明的目的在于提供12-酮基石胆酸在抗咽峡炎链球菌中的应用。
本发明所采取的技术方案是：
本发明的第一方面，提供12-酮基石胆酸或其药学上可接受的盐在制备抗咽峡炎链球菌感染的产品中的应用。
本发明的第二方面，提供12-酮基石胆酸或其药学上可接受的盐在制备抑制咽峡炎链球菌生长的产品中的应用。
本发明的第三方面，提供12-酮基石胆酸或其药学上可接受的盐在非疾病诊断治疗目的地抑制咽峡炎链球菌生长中的应用。
本发明的第四方面，提供12-酮基石胆酸或其药学上可接受的盐在制备用于预防和/或治疗由咽峡炎链球菌导致的疾病的产品中的应用。
优选地，所述由咽峡炎链球菌导致的疾病包括中耳炎、鼻窦炎、脑内脓肿、牙龈炎、牙周炎、牙脓肿、肺炎、肺脓肿、胸膜脓胸和腹腔内感染等。
优选地，所述产品包括抑菌剂、药物或添加剂。
优选地，所述添加剂包括食品添加剂、饲料添加剂或卫生产品添加剂。
优选地，所述产品中还包括药学上、添加剂中可接受的辅料。
优选地，所述辅料包括载体、稀释剂、赋形剂、润滑剂、粘合剂、湿润剂、崩解剂、溶剂、乳化剂、助溶剂、增溶剂、防腐剂、pH调节剂、渗透压调节剂、表面活性剂、包衣材料、抗氧剂或缓冲剂中的至少一种。
优选地，所述产品的剂型选自乳剂、膏剂、气雾剂、悬浮剂、可湿性粉剂、粉剂、粒剂、水剂中的至少一种。
本发明的第五方面，提供一种产品，包括12-酮基石胆酸或其药学上可接受的盐；
所述产品具有以下至少一种作用：
A1、抗咽峡炎链球菌感染；
A2、抑制咽峡炎链球菌生长；
A3、预防和/或治疗由咽峡炎链球菌导致的疾病。
优选地，所述产品包括抑菌剂、药物或添加剂。
优选地，所述添加剂包括食品添加剂、饲料添加剂或卫生产品添加剂。
本发明的第六方面，提供一种非疾病诊断治疗目的地抑制咽峡炎链球菌生长的方法，包括以下步骤：
使用12-酮基石胆酸或其药学上可接受的盐，或本发明第五方面所述的产品抑制咽峡炎链球菌生长。
优选地，所述12-酮基石胆酸的工作浓度为3～400μg/mL。
优选地，所述12-酮基石胆酸的工作浓度为3～100μg/mL。
本发明的有益效果是：
本发明首次发现了12-酮基石胆酸对咽峡炎链球菌能够抑制咽峡炎链球菌的生长，且IC50为3.805μg/ml；因此12-酮基石胆酸可以用于制备抗咽峡炎链球菌的产品，从而有效治疗咽峡炎链球菌感染或由咽峡炎链球菌感染导致的疾病；具有很好的应用前景。
附图说明
图1：12-酮基石胆酸浓度与咽峡炎链球菌生长抑制率关系图。
图2：氯霉素浓度与缓症链球菌生长抑制率关系图。
具体实施方式
以下将结合实施例对本发明的构思及产生的技术效果进行清楚、完整地描述，以充分地理解本发明的目的、特征和效果。显然，所描述的实施例只是本发明的一部分实施例，而不是全部实施例，基于本发明的实施例，本领域的技术人员在不付出创造性劳动的前提下所获得的其他实施例，均属于本发明保护的范围。
本实施例中国咽峡炎链球菌ATCC9895购于宁波明舟生物科技有限公司，12-酮基石胆酸和氯霉素均为市售品，其中12-酮基石胆酸的具体信息为：产品编号：700239P；品牌：Avanti；氯霉素的具体信息为：产品编号：56757；品牌：MACKLIN。
实施例1
1、样品准备
1.1供试品：12-酮基石胆酸；分子量：390.56g/mol；
供试品临用前用乙醇配制成最大浓度50mg/mL，依次对倍稀释。
1.2对照品：氯霉素。
2、测试菌株及培养方法
测试菌株为咽峡炎链球菌ATCC9895，培养条件：Brain-Heart Infusion(BHI)，37℃孵育24h-48h。
具体培养步骤如下：
2.1菌种开启接种并培养
用浸过75％酒精的脱脂棉擦净安瓿管，用火焰加热其顶端，滴少量(2-3滴)无菌水至加热顶端使之破裂，用锉刀或者镊子敲下已破裂的安瓿管顶端并将冻干管开口处在火焰上过一遍，用无菌吸管吸取0.3ml的无菌水，滴入冻干管中，轻轻振荡至其溶解。吸取全部菌悬液，接种在哥伦比亚血琼脂培养基上，37℃培养24小时后，挑取单个菌落于液体培养基中在相同的培养条件下培养增菌。
2.2菌液工作液的准备
当OD600值达到0.6左右(约109CFU/ml)，经BHI肉汤梯度稀释(0、10、100、1000、10000、100000、10000倍)后，取100μL菌悬液接种于固体培养基上，培养24h后计数活菌数，计算菌悬液浓度，再将此混悬菌液进行稀释，使菌悬液最终浓度约为2×106CFU/ml。菌种操作均在无菌条件下进行，实验完毕，所有耗材经灭菌再做丢弃处理。
3、抑制50％受试菌所需最低抑菌浓度的测定(MIC50)
3.1测试方法：采取微量肉汤稀释法，进行MIC50的测定。
实验分为阳性对照组(即不含药物的菌悬液)、阴性对照组(含溶媒乙醇的培养基)和实验组(含不同浓度的12-酮基石胆酸菌悬液)。以上各组均设置3个平行组。将浓度为300μg/mL的12-酮基石胆酸实验液按对倍稀释溶于液体培养基中，使其终浓度为300μg/mL、150μg/mL、75μg/mL、37.5μg/mL、18.75μg/mL、9.375μg/mL、4.6875μg/mL、0μg/mL。浓度为2×106CFU·mL-1菌悬液与各组药液按比例1：1各100μL，分别接种于无菌96孔板中，使菌悬液的终浓度为1×106CFU/mL(含105CFU/孔)，置于适当的培养条件下培养24h。
同时设置对照品氯霉素，使其终浓度分别为32μg/mL、16μg/mL、8μg/mL、4μg/mL、2μg/mL、1μg/mL、0μg/mL。培养结束后，在黑色背景下进行肉眼观察，平皿内未见细菌生长的最低药物浓度即为12-酮基石胆酸的最低抑菌浓度(MIC)。所有菌种的IC测定实验重复3次。
悬浮菌体测OD600值，不同浓度的供试品及对照品抑菌率的计算方法：抑菌率(％)＝1-(供试品/对照品OD值—阴性对照OD值)/(阳性对照OD值—阴性对照OD值)×100％。通过曲线拟合得函数计算而得MIC50。
本次试验结果见表1-表2，抑制率图见图1-图2；当阳性对照孔(即不含药物)内细菌明显生长，试验才有意义。
表1：不同浓度12-酮基石胆酸对咽峡炎链球菌生长影响的吸光值测定
表2：不同浓度氯霉素对缓症链球菌生长影响的吸光值测定
结果显示，阳性对照孔(即不含药物)内细菌正常生长，溶媒对照培养基孔无菌生长。对照品氯霉素对缓症链球菌的MIC值为4μg/mL，符合美国临床实验室标准化委员会(National committee for clinical library standardization,NCCLS)2001年的《抗微生物药物敏感试验的执行标准：第十一版信息增刊》M100-S11中氯霉素对缓症链球菌≤4μg/mL的标准，说明本实验方法是可靠的。
统计结果表明：12-酮基石胆酸对受试的咽峡炎链球菌的IC50为3.805μg/mL。结果表明，12-酮基石胆酸有良好的抑制咽峡炎链球菌活性，研究结果以期为临床医生防控咽峡炎链球菌提供参考。
上述具体实施方式对本发明作了详细说明，但是本发明不限于上述实施例，在所属技术领域普通技术人员所具备的知识范围内，还可以在不脱离本发明宗旨的前提下作出各种变化。此外，在不冲突的情况下，本发明的实施例及实施例中的特征可以相互组合。
Claims (10)
1.12-酮基石胆酸或其药学上可接受的盐在制备抗咽峡炎链球菌感染的产品中的应用。
2.12-酮基石胆酸或其药学上可接受的盐在制备抑制咽峡炎链球菌生长的产品中的应用。
3.12-酮基石胆酸或其药学上可接受的盐在制备用于预防和/或治疗由咽峡炎链球菌导致的疾病的产品中的应用。
4.12-酮基石胆酸或其药学上可接受的盐在非疾病诊断治疗目的地抑制咽峡炎链球菌生长中的应用。
5.根据权利要求1～3任一项所述的应用，其特征在于，所述产品包括抑菌剂、药物或添加剂。
6.根据权利要求5所述的应用，其特征在于，所述添加剂包括食品添加剂、饲料添加剂或卫生产品添加剂。
7.根据权利要求5所述的应用，其特征在于，所述产品还包括辅料。
8.一种产品，包括12-酮基石胆酸或其药学上可接受的盐；所述产品具有以下至少一种作用：
A1、抗咽峡炎链球菌感染；
A2、抑制咽峡炎链球菌生长；
A3、预防和/或治疗由咽峡炎链球菌导致的疾病。
9.一种非疾病诊断治疗目的地抑制咽峡炎链球菌生长的方法，包括以下步骤：使用12-酮基石胆酸或其药学上可接受的盐，或权利要求8所述的产品抑制咽峡炎链球菌生长。
10.根据权利要求9所述的方法，其特征在于，所述12-酮基石胆酸的工作浓度为3～400μg/mL。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311376447.4A CN117599068A (zh) | 2023-10-23 | 2023-10-23 | 12-酮基石胆酸在制备抗咽峡炎链球菌产品中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311376447.4A CN117599068A (zh) | 2023-10-23 | 2023-10-23 | 12-酮基石胆酸在制备抗咽峡炎链球菌产品中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117599068A true CN117599068A (zh) | 2024-02-27 |
Family
ID=89946954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311376447.4A Pending CN117599068A (zh) | 2023-10-23 | 2023-10-23 | 12-酮基石胆酸在制备抗咽峡炎链球菌产品中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117599068A (zh) |
-
2023
- 2023-10-23 CN CN202311376447.4A patent/CN117599068A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2022048061A1 (zh) | 一种耐高温宽裂解谱的沙门氏菌噬菌体及其组合物 | |
| US9724295B2 (en) | Compositions for topical treatment of microbial infections | |
| EP2501375B1 (en) | Antimicrobial compositions containing free fatty acids | |
| CN105031609B (zh) | 含抗菌肽Cbf-14的消毒剂及其制备和用途 | |
| WO2019144830A1 (zh) | 一种宽裂解谱绿脓杆菌噬菌体及其消毒应用 | |
| CN111096964A (zh) | 一种槲皮素与抗菌药物的联合应用 | |
| CN109402002A (zh) | 一种加氏乳杆菌及其在制备预防早产药物中的应用 | |
| WO2014019485A1 (zh) | 广藿香酮的新用途 | |
| CN110151752A (zh) | 一种茶多酚类组合物及其在制备抗猪链球菌药物中的应用 | |
| Boukahil et al. | Mutual antagonism between Mannheimia haemolytica and Pasteurella multocida when forming a biofilm on bovine bronchial epithelial cells in vitro | |
| CN117599068A (zh) | 12-酮基石胆酸在制备抗咽峡炎链球菌产品中的应用 | |
| CN112189670A (zh) | 一种无腐蚀无刺激具有消毒功能的卫生湿巾及其制造方法 | |
| AU2015237234B2 (en) | Preparation of small colony variants of therapeutic bacteria | |
| CN114702554A (zh) | 抗菌肽nzx在制备无乳链球菌抗菌药物中的应用 | |
| CN115531395B (zh) | 脱氧胆酸在制备抗婴儿链球菌的产品中的应用 | |
| CN115364107B (zh) | 石胆酸的用途 | |
| JP2014512408A (ja) | アルキルポリグルコシドをベースとする膣用組成物 | |
| CN115531394B (zh) | 脱氧胆酸在制备抗缓症链球菌的产品中的应用 | |
| JP6589648B2 (ja) | 腸球菌検出用培地及び腸球菌検出法 | |
| WO2021182377A1 (ja) | クロストリディオイデス ディフィシル菌増殖抑制剤 | |
| CN106176810A (zh) | 药用纳米材料组合物dg‑5用于抗耐药菌的用途 | |
| CN114940977A (zh) | 一株鸭沙门氏菌噬菌体、其噬菌体组合物及其在防治鸭沙门氏菌感染的疾病中的应用 | |
| JP2018002661A (ja) | 抗菌防腐剤組成物及びそれを用いた組成物 | |
| Hamad et al. | Anticancer potential of aqueous Dianthus Caryophyllus L. extract on MCF-7 human breast cancer cell line and antibacterial activity on Pseudomonas Aeruginosa isolated from human wounds | |
| Malakhia | Comparison of methods for detection of biofilm formation by Pseudomonas aeruginosa isolated from canine ear infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |